- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Mantle cell lymphoma (MCL)
- Meeting Date: July 2026
Acalabrutinib – July 2026
- Tablet 100 mg
Public Summary Documents
Last updated
13 November 2026
